NOVATARG, INC.

Biotech · Acquired

Novel biguanide small molecule (NT1195) for type 2 diabetes treatment in patients with kidney disease

Grants
$5.5M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
3 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel and Kidney Selective AMPK Activators to Treat Polycystic Kidney Disease$474,273
Federal grantDepartment of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes$1,639,823
Federal grantDepartment of Health and Human Services · Phase II · Novel and Kidney Selective AMPK Activators to Treat Polycystic Kidney Disease$1,109,281
Federal grantDepartment of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes$987,938
Federal grantDepartment of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes$284,611
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2136Richard Fisher——
2137PLEXYMER, INC.——
2138SGN, Inc.—$3.8M
2139NOVATARG, INC.——
2140Helix Alternative Technologies Inc.—$6.0M
2141ImmunoMolecular Therapeutics, Inc.—$11M
2142CELLECHO INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 5

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.